Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey
Michel Krempf, Ross J Simpson Jr, Dena Rosen Ramey, Philippe Brudi, Hilde Giezek, Joanne E Tomassini, Raymond Lee, Michel Farnier, Michel Krempf, Ross J Simpson Jr, Dena Rosen Ramey, Philippe Brudi, Hilde Giezek, Joanne E Tomassini, Raymond Lee, Michel Farnier
Abstract
Background: Goal attainment of guideline-recommended low-density lipoprotein cholesterol (LDL-C) is suboptimal. Little is known about how patient factors influence physicians' treatment decision-making in hypercholesterolemia. We examined physicians' treatment recommendations in high-risk patients whose LDL-C remained uncontrolled despite statin monotherapy.
Methods: Physicians completed a questionnaire prior to randomization into period I of a two-period randomized controlled trial evaluating LDL-C goal attainment in patients whose LDL-C remained ≥100 mg/dL after 5 weeks' treatment with atorvastatin 10 mg/day (NCT01154036). Physicians' treatment recommendations were surveyed for two hypothetical and one real scenario: (1) LDL-C presumed near goal (between 100-105 mg/dL), (2) LDL-C presumed far from goal (~120 mg/dL), and (3) observed baseline LDL-C of enrolled patients. Prognostic factors considered during decision-making were identified by regression analysis. Observed lipid outcomes at the end of period I (following 6 weeks' treatment with ezetimibe 10 mg plus atorvastatin 10 mg, atorvastatin 20 mg, or rosuvastatin 10 mg) were compared with estimated LDL-C outcomes for physicians' treatment recommendations after 6 weeks (based on individual patients' pre-randomization LDL-C and expected incremental change).
Results: Questionnaires were completed for 1,534 patients. No change in therapy, or double atorvastatin dose, were frequently recommended, even when LDL-C was far from goal (6.5% and 52.2% of patients, respectively). Double atorvastatin dose was commonly recommended in all scenarios (43-52% of patients). More intensive LDL-C-lowering regimens were recommended infrequently e.g. double atorvastatin dose and add ezetimibe only <12% in all scenarios. Overall, cardiovascular risk factors and desire to achieve a more aggressive LDL-C goal were prominent factors in decision-making for treatment. Comparison of observed and estimated LDL-C levels showed that physicians tended to overestimate the effectiveness of their recommendations.
Conclusions: This study provides insight into physicians' perspectives on clinical management of hypercholesterolemia and highlights a gap in knowledge translation from guidelines to clinical practice. The need for lower LDL-C and cardiovascular risk were key drivers in clinical decision-making, but physicians' treatment choices were more conservative than guideline recommendations, potentially resulting in poorer LDL-C reduction. When compared with actual outcomes, projected LDL-C control was better if physicians used more comprehensive strategies rather than simply doubling the statin dose.
Trial registration: Clinicaltrials.gov: NCT01154036.
Figures
References
- Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. doi: 10.1016/S0140-6736(10)61350-5.
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
- Perk J, De BG, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Atherosclerosis. 2012;223:1–68. doi: 10.1016/j.atherosclerosis.2012.05.007.
- Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–934. doi: 10.1016/j.jacc.2013.11.002.
- Catapano AL, Reiner Z, De BG, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS) Atherosclerosis. 2011;217:3–46. doi: 10.1016/j.atherosclerosis.2011.06.028.
- Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151–67. doi: 10.1016/j.cjca.2012.11.032.
- Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, et al. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. Vasc Health Risk Manag. 2014;10:237–46. doi: 10.2147/VHRM.S54886.
- Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF. Achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol. 2011;107:886–90. doi: 10.1016/j.amjcard.2010.11.006.
- Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;19:221–30. doi: 10.1177/1741826711400545.
- International Atherosclerosis Society (IAS). An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia. . (2013). Accessed 13 Nov 2013.
- Smith SC, Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the national heart, lung, and blood institute. Circulation. 2006;113:2363–72. doi: 10.1161/CIRCULATIONAHA.106.174516.
- Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - executive summary. J Clin Lipidol. 2014;8:473–88. doi: 10.1016/j.jacl.2014.07.007.
- Kauffman AB, Olson KL, Youngblood ML, Zadvorny EB, Delate T, Merenich JA. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. J Clin Lipidol. 2010;4:173–80. doi: 10.1016/j.jacl.2010.03.002.
- Karalis DG, Victor B, Ahedor L, Liu L. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol. 2012;2012:861924. doi: 10.1155/2012/861924.
- Rublee DA, Burke JP. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad Med. 2010;122:16–24. doi: 10.3810/pgm.2010.03.2118.
- Willey VJ, Bullano MF, Shoetan NN, Gandhi SK. Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Curr Med Res Opin. 2010;26:121–8. doi: 10.1185/03007990903426811.
- Foley KA, Denke MA, Kamal-Bahl S, Simpson R, Jr, Berra K, Sajjan S, et al. The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients. Med Care. 2006;44:421–8. doi: 10.1097/01.mlr.0000208017.18278.1a.
- Rashidian A, Russell I. Intentions and statins prescribing: can the theory of planned behaviour explain physician behaviour in following guideline recommendations? J Eval Clin Pract. 2011;17:749–57. doi: 10.1111/j.1365-2753.2011.01690.x.
- Aujoulat I, Jacquemin P, Rietzschel E, Scheen A, Trefois P, Wens J, et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract. 2014;5:141–7. doi: 10.2147/AMEP.S59022.
- Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De BG, et al. Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol. 2012;19:541–50. doi: 10.1177/1741826711407705.
- Solomon J, Raynor DK, Knapp P, Atkin K. The compatibility of prescribing guidelines and the doctor-patient partnership: a primary care mixed-methods study. Br J Gen Pract. 2012;62:e275–81. doi: 10.3399/bjgp12X636119.
- Goff DC, Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2935–59. doi: 10.1016/j.jacc.2013.11.005.
- Bays HE, Averna M, Majul C, Muller-Wieland D, De PA, Giezek H, et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol. 2013;112:1885–95. doi: 10.1016/j.amjcard.2013.08.031.
- Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, et al. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. J Clin Lipidol. 2014;8:107–16. doi: 10.1016/j.jacl.2013.09.009.
- Simpson RJ, Jr, Tunceli K, Ramey DR, Neff DR, Kern DM, Hsieh HM, et al. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. J Clin Lipidol. 2013;7:399–407. doi: 10.1016/j.jacl.2013.06.002.
- Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER) Am J Cardiol. 2010;105:69–76. doi: 10.1016/j.amjcard.2009.08.651.
- Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106–7. doi: 10.1016/S0002-9149(97)00298-1.
- Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–90. doi: 10.1016/S0140-6736(07)60716-8.
- Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, et al. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc Health Risk Manag. 2013;9:719–27. doi: 10.2147/VHRM.S49840.
- Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–61. doi: 10.1016/j.atherosclerosis.2012.02.016.
- Merck Sharp and Dohme Corp. Liptruzet® (ezetimibe and atorvastatin) Tablets Prescribing Information. . (2013). Accessed 13 Nov 2013.
- Merck Sharp and Dohme Corp. Vytorin® (ezetimibe/simvastatin) Tablets Prescribing Information. . (2013). Accessed 13 Nov 2013.
- Merck Sharp and Dohme Corp. Zetia® (ezetemibe) Tablets Prescribing Information. . (2013). Accessed 13 Nov 2013.
- Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis. 2014;237:829–37. doi: 10.1016/j.atherosclerosis.2014.10.105.
- Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. doi: 10.1056/NEJMoa1107579.
- Ginsberg HN, Elam MB, Lovato LC, Crouse JR, III, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74. doi: 10.1056/NEJMoa1001282.
- Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12. doi: 10.1056/NEJMoa1300955.
- Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92. doi: 10.1016/S0140-6736(11)60739-3.
- Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014;168:205–12. doi: 10.1016/j.ahj.2014.05.004.
- IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. . 2014. Accessed 28 Nov 2014.
- IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. On-Treatment Analysis. . 2014.
- Zafar A, Stone MA, Davies MJ, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of Type 2 diabetes in primary care: a qualitative study. Diabet Med. 2015;32:407–13. doi: 10.1111/dme.12592.
- Kitkungvan D, Lynn Fillipon NM, Dani SS, Downey BC. Low-density lipoprotein cholesterol target achievement in patients at high risk for coronary heart disease. J Clin Lipidol. 2010;4:293–7. doi: 10.1016/j.jacl.2010.06.003.
- Hermans MP, Elisaf M, Michel G, Muls E, Nobels F, Vandenberghe H, et al. Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized, controlled trial. Diabetes Care. 2013;36:3388–95. doi: 10.2337/dc12-1853.
- Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22:2041–53. doi: 10.1185/030079906X132721.
- Weinstock RS, Goldberg RB, Guyton JR, Mazzone T, Polis A, Tomassini JE, et al. Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. J Clin Lipidol. 2008;2:25–35. doi: 10.1016/j.jacl.2008.01.001.
- Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487–94. doi: 10.1016/j.amjcard.2004.02.060.
- Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005;149:464–73. doi: 10.1016/j.ahj.2004.11.023.
- Pfizer . Lipitor [package insert] New York, NY: Parke-Davis; 2009.
Source: PubMed